Preliminary positive findings led remdesivir to become a staple in the armamentarium to treat hospitalized patients with COVID-19, but the latest data from two large studies by the National Institutes of Health and the World Health Organization (WHO) indicate the drug provides no mortality benefit.
Despite this finding, on Oct. 22, the FDA approved remdesivir (Veklury, Gilead) as the first treatment indicated for COVID-19 (bit.ly/2TyC6h7).
The NIH COVID-19 treatment guidelines also continue to